Xinwei Yang
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Xinwei Yang has a total of 16 co-authors. Here are the top co-authors by number of shared publications:
- Liping Xu
School of Traditional Chinese Medicine, Capital Medical University, Beijing 100069, China
4 shared publications Xiao Li
School of Traditional Chinese Medicine, Capital Medical University, Beijing, China; Beijing Key Lab of TCM Collateral Disease Theory Research, Beijing, China
3 shared publicationsYanbo Zhu
School of Traditional Chinese Medicine, Capital Medical University, Beijing, China; Beijing Key Lab of TCM Collateral Disease Theory Research, Beijing, China
3 shared publicationsJiayue Zhu
School of Traditional Chinese Medicine, Capital Medical University, Beijing, China
2 shared publicationsShuo Han
School of Traditional Chinese Medicine, Capital Medical University, Beijing, China
2 shared publicationsDongqi Liu
School of Traditional Chinese Medicine, Capital Medical University, Beijing, China
1 shared publication
Latest Publications
- Open Access
- 28 July 2026
- Published by Springer Nature in BMC Complementary Medicine and Therapies
- Vol. 26 (1)
Effects of the extract of Ginkgo biloba L. on inflammatory response and mitochondrial dynamics in microglia in Alzheimer’s disease
- 28 July 2026
- Published by Springer Nature in BMC Complementary Medicine and Therapies
- Vol. 26 (1)
Open AccessEffects of the extract of Ginkgo biloba L. on inflammatory response and mitochondrial dynamics in microglia in Alzheimer’s disease
- 4 December 2025
- Published by Elsevier in Phytomedicine
- Vol. 150, 157656
Multi-level intervention of Tangluoning on mitochondrial thioredoxin deficiency in Schwann cells ameliorates diabetic peripheral neuropathy
- 4 December 2025
- Published by Elsevier in Phytomedicine
- Vol. 150, 157656
Multi-level intervention of Tangluoning on mitochondrial thioredoxin deficiency in Schwann cells ameliorates diabetic peripheral neuropathy
- Open Access
- 1 January 2022
- Published by Wiley in Oxidative Medicine and Cellular Longevity
- Vol. 2022 (1) , 4775645
Paeoniflorin Upregulates Mitochondrial Thioredoxin of Schwann Cells to Improve Diabetic Peripheral Neuropathy Indicated by 4D Label‐Free Quantitative Proteomics
Diabetic peripheral neuropathy (DPN) is a diabetic complication characterized by demyelination. The pathogenesis of DPN has not been fully elucidated, thus lacking therapies. In the current study, we aimed to confirm whether paeoniflorin (PF) could improve DPN by upregulating mitochondrial thioredoxin (Trx2) based on 4D Label‐free proteomic experiments of Schwann cells (SCs) mitochondria. Firstly, PF increased the expression of mitochondrial processing peptidase α (Pmpca) and small ubiquitin‐related modifier 1 (Sumo1) to increase mitochondrial protein processing of Trx2. Then, PF increased the protein expression of Trx reductase 2 (TrxR2) and peroxiredoxin 3 (Prx3), which belong to mitochondrial Trx systems. Accordingly, PF decreased mitochondrial reactive oxygen species (ROS) while increasing mtDNA and mitochondrial membrane potential to improve mitochondria function under high glucose environment. Furthermore, total glucosides of paeony capsules (TGP), containing more than 90% PF, increased the Trx2, TrxR2, and Prx3 levels in sciatic nerve of DPN rats, thus reducing demyelination as well as improving mechanical pain threshold, thermal pain threshold, motor nerve conduction velocity (MNCV), and sensor nerve conduction velocity (SNCV). Overall, these results suggest that PF could provide protection for DPN by upregulating Trx2.
- 1 January 2022
- Published by Wiley in Oxidative Medicine and Cellular Longevity
- Vol. 2022 (1) , 4775645
Open AccessPaeoniflorin Upregulates Mitochondrial Thioredoxin of Schwann Cells to Improve Diabetic Peripheral Neuropathy Indicated by 4D Label‐Free Quantitative Proteomics
Diabetic peripheral neuropathy (DPN) is a diabetic complication characterized by demyelination. The pathogenesis of DPN has not been fully elucidated, thus lacking therapies. In the current study, we aimed to confirm whether paeoniflorin (PF) could improve DPN by upregulating mitochondrial thioredoxin (Trx2) based on 4D Label‐free proteomic experiments of Schwann cells (SCs) mitochondria. Firstly, PF increased the expression of mitochondrial processing peptidase α (Pmpca) and small ubiquitin‐related modifier 1 (Sumo1) to increase mitochondrial protein processing of Trx2. Then, PF increased the protein expression of Trx reductase 2 (TrxR2) and peroxiredoxin 3 (Prx3), which belong to mitochondrial Trx systems. Accordingly, PF decreased mitochondrial reactive oxygen species (ROS) while increasing mtDNA and mitochondrial membrane potential to improve mitochondria function under high glucose environment. Furthermore, total glucosides of paeony capsules (TGP), containing more than 90% PF, increased the Trx2, TrxR2, and Prx3 levels in sciatic nerve of DPN rats, thus reducing demyelination as well as improving mechanical pain threshold, thermal pain threshold, motor nerve conduction velocity (MNCV), and sensor nerve conduction velocity (SNCV). Overall, these results suggest that PF could provide protection for DPN by upregulating Trx2.
- Open Access
- 22 July 2021
- Published by Frontiers Media SA in Frontiers in Pharmacology
- Vol. 12, 718452
Corrigendum: Tang Luo Ning, a Traditional Chinese Compound Prescription, Ameliorates Schwannopathy of Diabetic Peripheral Neuropathy Rats by Regulating Mitochondrial Dynamics In Vivo and In Vitro
Corrigendum: Tang Luo Ning, a Traditional Chinese Compound Prescription, Ameliorates Schwannopathy of Diabetic Peripheral Neuropathy Rats by Regulating Mitochondrial Dynamics In Vivo and In Vitro
- 22 July 2021
- Published by Frontiers Media SA in Frontiers in Pharmacology
- Vol. 12, 718452
Open AccessCorrigendum: Tang Luo Ning, a Traditional Chinese Compound Prescription, Ameliorates Schwannopathy of Diabetic Peripheral Neuropathy Rats by Regulating Mitochondrial Dynamics In Vivo and In Vitro
Corrigendum: Tang Luo Ning, a Traditional Chinese Compound Prescription, Ameliorates Schwannopathy of Diabetic Peripheral Neuropathy Rats by Regulating Mitochondrial Dynamics In Vivo and In Vitro
- Open Access
- 14 May 2021
- Published by Frontiers Media SA in Frontiers in Pharmacology
- Vol. 12
Tang Luo Ning, a Traditional Chinese Compound Prescription, Ameliorates Schwannopathy of Diabetic Peripheral Neuropathy Rats by Regulating Mitochondrial Dynamics In Vivo and In Vitro
Tang Luo Ning (TLN), a traditional Chinese compound prescription, has been used clinically to treat diabetic peripheral neuropathy (DPN) in China. However, the exact mechanisms remain unclear. The objective of this study is to unravel the effects of TLN on mitochondrial dynamics of DPN in streptozotocin-induced rat models and Schwann cells cultured in 150 mM glucose. Mitochondrial function was determined by Ca2+ and ATP levels of streptozotocin (STZ)-induced DPN rats and mitochondria structure, mitochondrial membrane potential (MMP), and mtDNA of high glucose incubated SCs. Mitochondrial dynamics protein including mitofusin 1 (Mfn1), mitofusin 2 (Mfn2), optic atrophy 1 (Opa1), and dynamin-related protein 1 (Drp1) were investigated using Western blot or immunofluorescence. Myelin basic protein (MBP), myelin protein zero (MPZ), and sex-determining region Y (SRY)-box 10 (Sox10) were measured to represent schwannopathy. Our results showed that TLN increased ATP levels (0.38 of model, 0.69 of HTLN, 0.61 of LTLN, P<0.01; 0.52 of 150 mM glucose, 1.00 of 10% TLN, P<0.01, 0.94 of 1% TLN, P<0.05), MMP (0.56 of 150 mM glucose, P<0.01, 0.75 of 10% TLN, P<0.05, 0.83 of 1% TLN, P<0.01), and mtDNA (0.32 of 150 mM glucose, 0.43 of 10% TLN, P<0.01) while decreased Ca2+ (1.54 of model, 1.06 of HTLN, 0.96 of LTLN, P<0.01) to improve mitochondrial function in vivo and in vitro. TLN helps maintain balance of mitochondrial dynamics: it reduces the mitochondria number (1.60 of 150 mM glucose, 1.10 of 10% TLN, P<0.01) and increases the mitochondria coverage (0.51 of 150 mM glucose, 0.80 of 10% TLN, 0.87 of 1% TLN, P<0.01), mitochondrial network size (0.51 of 150 mM glucose, 0.95 of 10% TLN, 0.94 of 1% TLN, P<0.01), and branch length (0.63 of 150 mM glucose, P<0.01, 0.73 of 10% TLN, P<0.05, 0.78 of 1% TLN, P<0.01). Further, mitochondrial dynamics–related Mfn1 (0.47 of model, 0.82 of HTLN, 0.77 of LTLN, P<0.01; 0.42 of 150 mM glucose, 0.56 of 10% TLN, 0.57 of 1% TLN, P<0.01), Mfn2 (0.40 of model, 0.84 of HTLN, 0.63 of LTLN, P<0.01; 0.46 of 150 mM glucose, 1.40 of 10% TLN, 1.40 of 1% TLN, P<0.01), and Opa1 (0.58 of model, 0.71 of HTLN, 0.90 of LTLN, P<0.01; 0.69 of 150 mM glucose, 0.96 of 10% TLN, 0.98 of 1% TLN, P<0.05) were increased, while Drp1 (1.39 of model, 0.96 of HTLN, 1.18 of LTLN, P<0.01; 1.70 of 150 mM glucose, 1.20 of 10% TLN, 1.10 of 1% TLN, P<0.05), phosphorylated Drp1 (2.61 of model, 1.44 of HTLN, P<0.05; 2.80 of 150 mM glucose, 1.50 of 10% TLN, 1.30 of 1% TLN, P<0.01), and Drp1 located in mitochondria (1.80 of 150 mM glucose, 1.00 of 10% TLN, P<0.05) were decreased after treatment with TLN. Additionally, TLN improved schwannopathy by increasing MBP (0.50 of model, 1.05 of HTLN, 0.94 of HTLN, P<0.01; 0.60 of 150 mM glucose, 0.78 of 10% TLN, P<0.01, 0.72 of 1% TLN, P<0.05), Sox101 (0.41 of model, 0.99 of LTLN, P<0.01; 0.48 of 150 mM glucose, 0.65 of 10% TLN, P<0.05, 0.69 of 1% TLN, P<0.01), and MPZ (0.48 of model, 0.66 of HTLN, 0.55 of HTLN, P<0.01; 0.60 of 150 mM glucose, 0.78 of 10% TLN, P<0.01, 0.75 of 1% TLN, P<0.05) expressions. In conclusion, our study indicated that TLN’s function on DPN may link to the improvement of the mitochondrial dynamics, which provides scientific evidence for the clinical application.
- 14 May 2021
- Published by Frontiers Media SA in Frontiers in Pharmacology
- Vol. 12
Open AccessTang Luo Ning, a Traditional Chinese Compound Prescription, Ameliorates Schwannopathy of Diabetic Peripheral Neuropathy Rats by Regulating Mitochondrial Dynamics In Vivo and In Vitro
Tang Luo Ning (TLN), a traditional Chinese compound prescription, has been used clinically to treat diabetic peripheral neuropathy (DPN) in China. However, the exact mechanisms remain unclear. The objective of this study is to unravel the effects of TLN on mitochondrial dynamics of DPN in streptozotocin-induced rat models and Schwann cells cultured in 150 mM glucose. Mitochondrial function was determined by Ca2+ and ATP levels of streptozotocin (STZ)-induced DPN rats and mitochondria structure, mitochondrial membrane potential (MMP), and mtDNA of high glucose incubated SCs. Mitochondrial dynamics protein including mitofusin 1 (Mfn1), mitofusin 2 (Mfn2), optic atrophy 1 (Opa1), and dynamin-related protein 1 (Drp1) were investigated using Western blot or immunofluorescence. Myelin basic protein (MBP), myelin protein zero (MPZ), and sex-determining region Y (SRY)-box 10 (Sox10) were measured to represent schwannopathy. Our results showed that TLN increased ATP levels (0.38 of model, 0.69 of HTLN, 0.61 of LTLN, P<0.01; 0.52 of 150 mM glucose, 1.00 of 10% TLN, P<0.01, 0.94 of 1% TLN, P<0.05), MMP (0.56 of 150 mM glucose, P<0.01, 0.75 of 10% TLN, P<0.05, 0.83 of 1% TLN, P<0.01), and mtDNA (0.32 of 150 mM glucose, 0.43 of 10% TLN, P<0.01) while decreased Ca2+ (1.54 of model, 1.06 of HTLN, 0.96 of LTLN, P<0.01) to improve mitochondrial function in vivo and in vitro. TLN helps maintain balance of mitochondrial dynamics: it reduces the mitochondria number (1.60 of 150 mM glucose, 1.10 of 10% TLN, P<0.01) and increases the mitochondria coverage (0.51 of 150 mM glucose, 0.80 of 10% TLN, 0.87 of 1% TLN, P<0.01), mitochondrial network size (0.51 of 150 mM glucose, 0.95 of 10% TLN, 0.94 of 1% TLN, P<0.01), and branch length (0.63 of 150 mM glucose, P<0.01, 0.73 of 10% TLN, P<0.05, 0.78 of 1% TLN, P<0.01). Further, mitochondrial dynamics–related Mfn1 (0.47 of model, 0.82 of HTLN, 0.77 of LTLN, P<0.01; 0.42 of 150 mM glucose, 0.56 of 10% TLN, 0.57 of 1% TLN, P<0.01), Mfn2 (0.40 of model, 0.84 of HTLN, 0.63 of LTLN, P<0.01; 0.46 of 150 mM glucose, 1.40 of 10% TLN, 1.40 of 1% TLN, P<0.01), and Opa1 (0.58 of model, 0.71 of HTLN, 0.90 of LTLN, P<0.01; 0.69 of 150 mM glucose, 0.96 of 10% TLN, 0.98 of 1% TLN, P<0.05) were increased, while Drp1 (1.39 of model, 0.96 of HTLN, 1.18 of LTLN, P<0.01; 1.70 of 150 mM glucose, 1.20 of 10% TLN, 1.10 of 1% TLN, P<0.05), phosphorylated Drp1 (2.61 of model, 1.44 of HTLN, P<0.05; 2.80 of 150 mM glucose, 1.50 of 10% TLN, 1.30 of 1% TLN, P<0.01), and Drp1 located in mitochondria (1.80 of 150 mM glucose, 1.00 of 10% TLN, P<0.05) were decreased after treatment with TLN. Additionally, TLN improved schwannopathy by increasing MBP (0.50 of model, 1.05 of HTLN, 0.94 of HTLN, P<0.01; 0.60 of 150 mM glucose, 0.78 of 10% TLN, P<0.01, 0.72 of 1% TLN, P<0.05), Sox101 (0.41 of model, 0.99 of LTLN, P<0.01; 0.48 of 150 mM glucose, 0.65 of 10% TLN, P<0.05, 0.69 of 1% TLN, P<0.01), and MPZ (0.48 of model, 0.66 of HTLN, 0.55 of HTLN, P<0.01; 0.60 of 150 mM glucose, 0.78 of 10% TLN, P<0.01, 0.75 of 1% TLN, P<0.05) expressions. In conclusion, our study indicated that TLN’s function on DPN may link to the improvement of the mitochondrial dynamics, which provides scientific evidence for the clinical application.